Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time.

Scosyrev E, Wu G, Mohile S, Messing EM.

Cancer. 2012 Dec 1;118(23):5768-76. doi: 10.1002/cncr.27503. Epub 2012 Jul 30.

PMID:
22847578
[PubMed - indexed for MEDLINE]
Free Article
2.

Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, Feuer EJ.

J Natl Cancer Inst. 2002 Jul 3;94(13):981-90.

PMID:
12096083
[PubMed - indexed for MEDLINE]
Free Article
3.

Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.

Welch HG, Albertsen PC.

J Natl Cancer Inst. 2009 Oct 7;101(19):1325-9. doi: 10.1093/jnci/djp278. Epub 2009 Aug 31.

PMID:
19720969
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Population screening for prostate cancer and emerging concepts for young men.

Moul JW.

Clin Prostate Cancer. 2003 Sep;2(2):87-97. Review.

PMID:
15040869
[PubMed - indexed for MEDLINE]
5.

Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Pinsky PF, Blacka A, Kramer BS, Miller A, Prorok PC, Berg C.

Clin Trials. 2010 Aug;7(4):303-11. doi: 10.1177/1740774510374091. Epub 2010 Jun 22.

PMID:
20571134
[PubMed - indexed for MEDLINE]
6.

Detection of prostate cancer via biopsy in the Medicare-SEER population during the PSA era.

Welch HG, Fisher ES, Gottlieb DJ, Barry MJ.

J Natl Cancer Inst. 2007 Sep 19;99(18):1395-400. Epub 2007 Sep 11.

PMID:
17848671
[PubMed - indexed for MEDLINE]
Free Article
7.

The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States.

Legler JM, Feuer EJ, Potosky AL, Merrill RM, Kramer BS.

Cancer Causes Control. 1998 Oct;9(5):519-27.

PMID:
9934717
[PubMed - indexed for MEDLINE]
8.

Trends in the stage specific incidence of prostate carcinoma in the Detroit metropolitan area, 1973-1994.

Schwartz KL, Severson RK, Gurney JG, Montie JE.

Cancer. 1996 Sep 15;78(6):1260-6.

PMID:
8826949
[PubMed - indexed for MEDLINE]
9.

Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death.

Hattangadi JA, Chen MH, D'Amico AV.

BJU Int. 2012 Dec;110(11):1636-41. doi: 10.1111/j.1464-410X.2012.11354.x. Epub 2012 Jul 3.

PMID:
22757982
[PubMed - indexed for MEDLINE]
10.

Trends in prostate cancer mortality among black men and white men in the United States.

Chu KC, Tarone RE, Freeman HP.

Cancer. 2003 Mar 15;97(6):1507-16.

PMID:
12627516
[PubMed - indexed for MEDLINE]
Free Article
11.

Towards an optimal interval for prostate cancer screening.

van Leeuwen PJ, Roobol MJ, Kranse R, Zappa M, Carlsson S, Bul M, Zhu X, Bangma CH, Schröder FH, Hugosson J.

Eur Urol. 2012 Jan;61(1):171-6. doi: 10.1016/j.eururo.2011.08.002. Epub 2011 Aug 10.

PMID:
21840117
[PubMed - indexed for MEDLINE]
12.

Prostate-specific antigen testing in black and white men: an analysis of medicare claims from 1991-1998.

Etzioni R, Berry KM, Legler JM, Shaw P.

Urology. 2002 Feb;59(2):251-5.

PMID:
11834397
[PubMed - indexed for MEDLINE]
13.

PSA screening and deaths from prostate cancer after diagnosis--a population based analysis.

Wachtel MS, Nelius T, Haynes AL, Dahlbeck S, de Riese W.

Prostate. 2013 Sep;73(12):1365-9. doi: 10.1002/pros.22680. Epub 2013 May 6.

PMID:
23649537
[PubMed - indexed for MEDLINE]
14.

The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence--data from the Utah Cancer Registry.

Stephenson RA, Smart CR, Mineau GP, James BC, Janerich DT, Dibble RL.

Cancer. 1996 Apr 1;77(7):1342-8.

PMID:
8608513
[PubMed - indexed for MEDLINE]
15.

Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer.

Moore AL, Dimitropoulou P, Lane A, Powell PH, Greenberg DC, Brown CH, Donovan JL, Hamdy FC, Martin RM, Neal DE.

BJU Int. 2009 Dec;104(11):1592-8. doi: 10.1111/j.1464-410X.2009.08652.x. Epub 2009 Jun 19.

PMID:
19549125
[PubMed - indexed for MEDLINE]
16.

Reduced risk of prostate cancer in U.S. Men with AIDS.

Shiels MS, Goedert JJ, Moore RD, Platz EA, Engels EA.

Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2910-5. doi: 10.1158/1055-9965.EPI-10-0741. Epub 2010 Sep 13.

PMID:
20837717
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.

Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H.

J Natl Cancer Inst. 2009 Mar 18;101(6):374-83. doi: 10.1093/jnci/djp001. Epub 2009 Mar 10.

PMID:
19276453
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

PSA-use in a Spanish industrial area.

Páez A, Luján M, Llanes L, Romero I, de la Cal MA, Miravalles E, Berenguer A.

Eur Urol. 2002 Feb;41(2):162-6.

PMID:
12074403
[PubMed - indexed for MEDLINE]
19.

Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

Hankey BF, Feuer EJ, Clegg LX, Hayes RB, Legler JM, Prorok PC, Ries LA, Merrill RM, Kaplan RS.

J Natl Cancer Inst. 1999 Jun 16;91(12):1017-24.

PMID:
10379964
[PubMed - indexed for MEDLINE]
Free Article
20.

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.

Welch HG, Schwartz LM, Woloshin S.

J Natl Cancer Inst. 2005 Aug 3;97(15):1132-7.

PMID:
16077071
[PubMed - indexed for MEDLINE]
Free Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk